How does niraparib kill cancer cells, and why does it work better in some patients than others?
Niraparib blocks PARP enzymes that repair broken DNA in cancer cells, forcing them to die. It works best in patients with BRCA mutations or homologous-recombination deficiency (HRD), but also helps patients without these mutations—just with smaller benefit [1][4].
In clinical trials, niraparib reduced the risk of cancer progression by 63% in newly diagnosed advanced ovarian cancer patients, with a median progression-free survival of 13.8 months versus 8.2 months on placebo [1]. In platinum-sensitive recurrent ovarian cancer, niraparib extended progression-free survival to 12.9 months compared to 5.5 months on placebo [8]. These numbers come straight from the FDA-approved PRIMA and NOVA trials, which enrolled over 1,000 patients combined.
Your cancer cells normally fix broken DNA using PARP enzymes—like tiny repair crews inside the cell nucleus. Niraparib shuts down those repair crews, so DNA damage piles up and the cancer cell dies through a process called apoptosis (programmed cell death) [4]. Patients with BRCA1/2 mutations or HRD already have weak DNA repair, so niraparib hits them twice as hard—their cells can't fix damage even without the drug.
In real-world practice, oncologists start niraparib at 300 mg once daily, then drop the dose to 200 mg or 100 mg if your blood counts drop too low or you develop high blood pressure [9]. Most patients tolerate the drug for 12–24 months before side effects force a break. Cost matters: retail is $107 per tablet, but insurance copays are usually $10–$50 monthly, and uninsured patients should ask about manufacturer copay cards [10].
Ask your oncologist: 'Do I have a BRCA mutation or HRD status?' If yes, niraparib is a strong first choice. If no, ask whether the benefit (a few extra months) is worth the side effects and cost for your specific cancer stage [1].